Please select the option that best describes you:
Topics:
Hematologic Malignancies • Medical Oncology • CML • Hematology • Journal Club ft. NEJM publications
In patients with CML who are receiving 1st line TKI with good molecular response, are you continuing therapy or switching to ascinimib based on the ASC4FIRST data?
Answer from: at Academic Institution
If patients are responding, I generally do not switch unless tolerance is an issue and dose reduction is not feasible/recommended.
Sign in or Register to read more